PGR and breast cancer: PR status was significantly different between BRCA1 and BRCA2 mutation carriers; BRCA2 carriers are more likely to develop progesterone receptor (PR) positive tumors and PR-negative breast cancer are associated with BRCA1 mutation carriers (p=0.000084).